Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Equities researchers at HC Wainwright issued their Q4 2024 earnings per share (EPS) estimates for Candel Therapeutics in a note issued to investors on Monday, November 18th. HC Wainwright analyst V. Bernardino anticipates that the company will earn ($0.30) per share for the quarter. HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Candel Therapeutics' current full-year earnings is ($0.91) per share.
Candel Therapeutics Stock Up 0.9 %
Shares of CADL traded up $0.04 during trading hours on Tuesday, reaching $3.99. The stock had a trading volume of 261,835 shares, compared to its average volume of 1,802,269. The firm has a 50-day simple moving average of $5.96 and a 200 day simple moving average of $6.69. Candel Therapeutics has a 12 month low of $0.77 and a 12 month high of $14.30. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 1.66. The company has a market capitalization of $129.60 million, a price-to-earnings ratio of -2.31 and a beta of -0.88.
Hedge Funds Weigh In On Candel Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Point72 DIFC Ltd bought a new stake in shares of Candel Therapeutics in the 2nd quarter worth approximately $31,000. FMR LLC bought a new position in Candel Therapeutics in the 3rd quarter worth about $46,000. MetLife Investment Management LLC purchased a new position in Candel Therapeutics during the 3rd quarter valued at about $87,000. Atom Investors LP purchased a new position in Candel Therapeutics during the third quarter valued at approximately $103,000. Finally, Rhumbline Advisers purchased a new position in shares of Candel Therapeutics during the 2nd quarter valued at $143,000. Hedge funds and other institutional investors own 13.93% of the company's stock.
Insiders Place Their Bets
In other news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.02, for a total value of $90,300.00. Following the completion of the sale, the insider now directly owns 929,873 shares of the company's stock, valued at $5,597,835.46. This represents a 1.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 31,800 shares of company stock worth $193,380. Insiders own 41.60% of the company's stock.
About Candel Therapeutics
(
Get Free Report)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
See Also
Before you consider Candel Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.
While Candel Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
